Sign In
Buy NTLA
$14.75
+1.73 (+13.29%)
At Close: Jun 04, 2026
Intellia Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress
07:30am, Thursday, 09'th May 2024
CAMBRIDGE, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therap
Just Say No to Drugs: 3 Pharma Stocks to Avoid
10:30am, Wednesday, 08'th May 2024
From its stellar performance in 2021 to deflating in 2022, the biotech sector continued its stagnation into 2023, highlighting some pharma stocks to avoid. Year-to-date, the S&P Biotechnology Select I
Why Intellia Therapeutics, Inc. (NTLA) Outpaced the Stock Market Today
07:16pm, Friday, 03'rd May 2024
In the latest trading session, Intellia Therapeutics, Inc. (NTLA) closed at $23.60, marking a +1.42% move from the previous day.
Shhh! 3 Secret Gene Editing Stocks Flying Below Wall Street's Radar
02:18pm, Friday, 03'rd May 2024
Gene editing stocks are among the most intriguing in the biotech scene. The genomics revolution may be as exciting as the ongoing artificial intelligence one.
Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2024 Earnings and Company Updates
07:30am, Thursday, 02'nd May 2024
CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therap
3 Gene Editing Stocks with the Potential to Make You an Overnight Millionaire
06:04am, Thursday, 02'nd May 2024
Pay close attention to gene editing stocks. By 2028, according to MarketsandMarkets, the market could be worth about $10.6 billion from $5.3 billion in 2023.
CAMBRIDGE, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based ther
Earnings Preview: Intellia Therapeutics, Inc. (NTLA) Q1 Earnings Expected to Decline
11:08am, Thursday, 25'th Apr 2024
Intellia Therapeutics (NTLA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
2 Stocks Down 30% to Buy Right Now
05:55am, Sunday, 14'th Apr 2024
Intellia is moving closer and closer to the finish line with two gene-editing candidates. Moderna's future looks bright again with new products on the way.
Bull Market and Beyond: 3 Stocks Just Waiting to Soar
04:50am, Tuesday, 09'th Apr 2024
These biotech stocks have missed out on market gains so far, falling in the double digits over the past year. But they are innovators with potential growth catalysts right around the corner.
Better Cathie Wood Stock: Moderna vs. Intellia
05:55am, Thursday, 28'th Mar 2024
Cathie Wood added to her positions in these biotech stocks this week. The famous investor seeks out undervalued innovators to add to her funds and hold onto for the long term.
Hot Stocks: The 3 Best Opportunities for Investing in Biotech
05:29pm, Thursday, 21'st Mar 2024
When it comes to risk vs. reward in the stock market, the biotech sector has one of the highest potential payoffs.
3 Stocks That Could Be the Next Big Thing in Gene Editing
04:19pm, Thursday, 21'st Mar 2024
Gene editing could revolutionize how millions of patients are treated all over the world. That could create big opportunities for some of the most exciting gene-editing stocks.
Intellia (NTLA) Begins Dosing in Phase III ATTR Amyloidosis Study
02:11pm, Tuesday, 19'th Mar 2024
Intellia (NTLA) doses the first patient in the phase III MAGNITUDE study on NTLA-2001 for treating transthyretin amyloidosis with cardiomyopathy.
CAMBRIDGE, Mass., March 18, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based ther
